Becton, Dickinson and Company (BD) has introduced the HemoSphere Alta platform, a haemodynamic monitoring system incorporating predictive AI-based algorithms to manage instability in blood pressure and enhance blood flow during medical procedures.
According to BD, this platform marks the first product from the company’s Advanced Patient Monitoring business.
Go deeper with GlobalData
One of the platform’s features is the cerebral autoregulation index (CAI), a parameter that indicates the brain’s ability to maintain stable blood flow amid blood pressure fluctuations, providing personalised insights into an individual’s blood pressure needs.
Clinicians can utilise the CAI through a combination of the ForeSight IQ Sensor on the forehead of the patient and the Acumen IQ Sensor attached to the arterial line.
Additionally, the platform comprises Acumen Hypotension Prediction Index (HPI) software, which can predict potential low blood pressure events.
This feature has been shown to decrease the duration, severity, and depth of hypotension in various multicentre trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe latest monitor also employs an enhanced design with a 15in high-resolution, touchscreen display, which is engineered to reduce disruptive pop-ups.
Features such as gesture and voice commands promote sterility and enable hands-free interaction with the monitor, including silencing alarms and changing views, providing an intuitive user interface.
BD Advanced Patient Monitoring president Tim Patz said: “HemoSphere Alta marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability.
“These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients.”
Last month, BD treated the first subject in the STANCE trial with the GalaFLEX LITE Scaffold, aimed at minimising the recurrence of capsular contracture (CC) during breast revision surgeries.
